TABLE 5-3 EPICOT Format for Formulating Future Research Recommendations

EPICOT Component

Issues to Consider

Example

E Evidence

What is the current evidence?

One systematic review dominated by a large randomized controlled study conducted in hospital setting

P Population

Diagnosis, disease stage, comorbidity, risk factor, sex, age, ethnic group, specific inclusion or exclusion criteria, clinical setting

Primary care patients with confirmed stroke or transient ischemic attack (mean age ≥ 75 years, female–male ratio 1:1, time since last cerebrovascular event ≥ 1 year)

I Intervention

Type, frequency, dose, duration, prognostic factor

Intensive blood pressure lowering

C Comparison

Placebo, routine care, alternative treatment/management

No active treatment or placebo

O Outcomes

Which clinical or patient-related outcomes will the researcher need to measure, improve, influence, or accomplish? Which methods of measurement should be used?

Major vascular events (stroke, myocardial infarction, vascular death); adverse events, risk of discontinuation of treatment because of adverse events

T Time stamp

Date of literature search or recommendation

February 2006

SOURCE: Brown et al. (2006).

transparency and trustworthiness of the review. The ACA contains a similar requirement for authors of research funded by PCORI.7

RECOMMENDED STANDARD FOR REPORT REVIEW

The committee recommends one overarching standard for review by scientific peers, other users and stakeholders, and the public:

Standard 5.2—Peer review the draft report

Required elements:

5.2.1

Use a third party to manage the peer review process

7

The Patient Protection and Affordable Care Act at § 6301(h)(3)(B).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement